A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
Major Depressive Disorder, Depression
About this trial
This is an interventional treatment trial for Major Depressive Disorder focused on measuring Depressive Disorder, Depressive Symptoms, Depressive Syndrome, Emotional Depression
Eligibility Criteria
Inclusion Criteria:
- with righthandedness;
- have first-episode MDD diagnosed as the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV); and
- HAMD-17 score is ≥ 20; and
- never had any psychoactive medications.
Exclusion Criteria:
- unstable medical conditions;
- have suicidal ideas or attempts or aggressive behavior;
- previously experienced manic, hypomanic, or mixed episode;
- immediate family members have bipolar or psychotic disorders;
- treatment with investigational drugs in past 6 months;
- alcoholism or drug abuse in past 1 year; or
- have needle phobia.
Sites / Locations
- School of Traditional Chinese Medicine, Southern Medical University
- Department of Psychiatry, Queen Mary Hospital
- Department of Psychiatry, Kowloon Hospital
- Department of Diagnostic Radiology, The University of Hong Kong
Arms of the Study
Arm 1
Arm 2
Active Comparator
Sham Comparator
DCEAS
n-CEA
Dense cranial electroacupuncture stimulation (DCEAS) For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Non-invasive cranial electroacupuncture (n-CEA) For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.